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The development of cancer immunotherapy and targeted
therapy has reached an important inflection point in the
history of melanoma. Immune checkpoint inhibitors and
kinase inhibitors are today’s standard of care treatments in
advanced melanoma patients. Treatment-related toxicities
can be very intriguing and quite challenging. Sarcoidosis is a
multisystemic granulomatous disease characterized by an
aberrant immune response to unknown antigens, whereas
sarcoid-like reactions (SLRs) refer to localized clinical
features. We carried out a single-center observational study
in patients with stage IIB–IV melanoma treated with
BRAF/MEK inhibitors and immune checkpoint inhibitors.
A description of the sarcoidosis-related manifestations was
provided from patients’ records. We observated eight cases
of SLRs in a cohort of 200 patients. The clinical courses
were characterized by a variety of symptoms, accompanied
by cutaneous signs and extracutaneous manifestations
such as bilateral, hilar lymphadenopathy. We identified a
histologically granulomatous inflammation involving the
skin, the lungs, and the lymph nodes. Two patients
presented with cutaneous lesions only, and three patients
had lung involvement only. Three patients achieved
complete and partial response of the melanoma disease,
and three patients had stable disease. Disease progression
was documented in two patients. The reported immune-
related adverse events were mild to severe and in most of
the cases were continued without any treatment cessation.
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Introduction
The development of cancer immunotherapy and targeted
therapy has reached an important inflection point in the
history of melanoma. The immune checkpoint inhibitors,
targeting either the cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) or the programmed cell death pro-
tein 1 (PD-1) and its ligand (PD-L1), as well as treatment
with the kinase inhibitors (BRAF and MEK inhibitors)
are current standard of care in advanced melanoma [1,2].
However, the treatment-related toxicities can be quite
challenging from the clinical, diagnostic, and therapeutic
point of view [3–5]. Sarcoidosis is a multisystemic gran-
ulomatous disease characterized by an aberrant immune
response to unknown antigens, initiated by T-helper
1 cells secreting interleukin-2 (IL-2) and interferon
(IFN)-γ, leading to the activation of additional T cells
and macrophages [6,7]. The diagnosis includes a typical
clinical and radiological presentation, accompanied
by histologically confirmed noncaseating granulomas and
exclusion of alternative diseases. In addition to sarcoi-
dosis, sarcoid-like reactions (SLRs), which refer to loca-
lized clinical features without fulfilling the sarcoidosis
criteria, increasingly occur during modern melanoma
therapy. Antineoplastic therapies, such as IFN, cisplatin,
and IL-2, have been previously associated with the
development of sarcoid-like reactions, mostly owing to
the macrophage and T-cell modulation [8].
Methods
A single-center retrospective analysis of patients with
stage IIB–IV melanoma (American Joint Committee on
Cancer, AJCC, 7th ed.) treated with BRAF/MEK and
immune checkpoint inhibitors was carried out in the
Dermatology Department of the University Hospital of
Zurich from January to May 2017 aiming to investigate
This is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-
ND), where it is permissible to download and share the work provided it is properly
cited. The work cannot be changed in any way or used commercially without
permission from the journal.
230 Original article
0960-8931 Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. DOI: 10.1097/CMR.0000000000000437
the frequency and the clinical and histological features of
SLRs in them. The patients were selected according to
the clinical and radiological presentation of the disease, as
well as the histological findings. Description of the clin-
ical reactions was provided from patients’ electronical
medical records. Skin biopsies were examined by a
board-certified dermatopathologist. Data were collected
according to the approval of the ethics commission (EK
no. 647/800) and following the guidelines of the Helsinki
Declaration on Human Rights.
Results
In total, we identified eight of 200 patients with melanoma
with a mean age of 56 years, who were at different clinical
stages of melanoma (AJCC stage IIB–IV) at the onset of the
SLR. Patients’ characteristics are shown in Table 1. None of
the patients had diabetes mellitus or arthritis before
appearance of SLRs. Two patients had additionally received
ipilimumab and BRAF/MEK inhibitors (vemurafenib and
LGX818/MEK162, respectively) before the onset of the
reaction (Table 1). These treatments are also known to be
potential inducers of sarcoid-like immune reactions. During
the onset of the SLR, three patients were treated with anti
PD-1 antibody [pembrolizumab as monotherapy or as a
combination with IDO-1/placebo within the keynote-252
study (NCT02752074)], two patients were under treatment
with kinase inhibitors [dabrafenib/trametinib and LGX818/
MEK162 within the logic-2 study (NCT02159066)], and
one patient received nivolumab or ipilimumab [BMS 238
study (NCT02060188)]. However, two patients were diag-
nosed with SLRs before any systemic therapy.
Among the patients who were diagnosed with a SLR
after treatment induction, the symptoms developed in a
median time of 5 months (range: 1–22 months). In all
patients, the reactions were characterized by a variety of
cutaneous signs and extracutaneous manifestations. The
radiological presentation was in five cases mediastinal
and hilar lymphadenopathy and in one case bilateral lung
lesions. Histological signs of skin sarcoidosis were either
skin granulomas or erythema nodosum. In one patient,
the diagnosis was suspected only radiologically. Evidence
of noncaseating granulomas was found in three patients
with lung and mediastinal lymph node involvement.
Two patients presented only with cutaneous lesions and
two patients had only systemic symptoms. All in all,
patients 5 and 7 met the criteria for systemic sarcoidosis.
In six of eight cases, the symptoms were mild to severe
and resumed without treatment cessation. Two patients
were treated with systemic steroids, 50 and 20 mg/daily
for 2 weeks, with complete recovery.
The melanoma response was measured according to the
RECIST 1.1. Three patients achieved complete response
or partial response during treatment and three patients had
a stable disease (SD). Two patients had a progressive
disease (PD) and one patient died owing to fatal disease
progression.
In this retrospective analysis, the prevalence of sarcoi-
dosis and SLRs in a cohort of 200 patients with melan-
oma was 4%, both under kinase and immune checkpoint
inhibitors.
Case 1
A 65-year-old male was diagnosed with AJCC (7th ed.) stage
IIIC melanoma of the right scapula region in 2016 (initial
Breslow tumor thickness 2.6mm, with ulceration). Following
surgical removal of the primary tumor, a regional lymphade-
nectomy was performed, which identified additional nodal
micrometastasis (1/9) and skin satellite-metastases (pN3).
A PET-computed tomography (CT) manifested multiple
other lymph node metastases and muscle metastases.
Subsequently, he was enrolled in the randomized, double-
blind, phase 3 keynote-252 clinical study (NCT02752074) of
pembrolizumab in combination with epacadostat (IDO inhi-
bitor) or placebo and had the first infusion of pembrolizumab
administered in December 2016. After completing the fourth
cycle of the therapy, he presented with reduced performance
status, dry cough, and B-symptoms. The clinical examination
revealed multiple subcutaneous nodules on the left elbow,
without any other skin symptoms (Fig. 1a). A biopsy of the
left elbow lesions showed granulomas infiltrates in the upper
dermis (Fig. 1b), and specific staining results for pathogens
(Ziehl–Neelsen and Brown–Brenn staining) were negative.
CT scan of the lungs confirmed bilateral enlargement of the
hilar lymph nodes without pulmonary parenchymal involve-
ment, which was not previously reported. Blood chemistry
and complete blood count were normal, aside from a mild
anemia and increased levels of sIL-2R. Angiotensin-
converting enzyme levels were measured and were normal
(44.2U/l, N<68). Quantiferon test (a IFN-γ release test for
Mycobacterium tuberculosis) result was shown to be positive,
even though previous exposure to M. tuberculosis was
unknown. The transbronchial biopsy of a mediastinal lymph
node diagnosed noncaseating epitheloid granulomas sur-
rounded by lymphocytes, typical for sarcoid granulomas.
Bronchoalveolar lavage revealed an increase of the lympho-
cytes portion by 33% with a CD4/CD8 quotient of 3.6. Both
PCR and microscopy findings were negative for
M. tuberculosis. Furthermore, both blood and tissue culture
findings were negative for mycobacteria and other pathogens.
Other infections ending in granulomatous inflammation were
unlikely owing to the clinical symptoms.
Taking these findings into account, the diagnosis of sar-
coidosis induced by pembrolizumab was suggested. The
patient received systemic corticosteroids (prednisolone
20mg/day for 12 days), and the symptoms resolved fully
within 2 weeks not requiring withdrawal from the study.
However, the patient stopped the treatment in March
2017 owing to fatal disease progression.
Case 2
A 57-year-old male was diagnosed with AJCC (7th ed.)
stage IIIB melanoma of the right lower leg in 2011 (initial
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Table 1 Cases of sarcoid-like reactions: features of patients’ characteristics, melanoma diagnosis and treatment as well as clinical and histological features of sarkoid-like reactions
Age
American Joint
Committee on
Cancer
(7th ed.) stage
Previous treatment
for melanoma
Treatment by onset of
sarcoid-like immune
reaction
Duration of
treatment
before onset of
sarcoidosis
Cutaneous
symptoms
Radiological
presentation
Histological
documentation Treatment
Outcome of
sarcoidosis
Treatment
cessation
Melanoma
response
73 (male) IV (M1a) Vemurafenib,
ipilimumab, and
LGX818/
MEK162 (logic-
2 study,
NCT02159066)
Pembrolizumab 15 months None Mediastinal and
hilar
lymphadenopathy
– None Not
recovered/
not
resolved
No CR
76 (male) IIB None None – None Mediastinal and
hilar
lymphadenopathy
Noncaseating
granuloma
(mediastinal lymph
nodes)
None Remission – PD
19 (male) IV (M1c) None Dabrafenib/trametinib 1 month Subcutaneous
nodules
None Erythema nodosum
(skin)
Topical
corticosteroids
Remission No CR
72 (male) IV (M1c) Ipilimumab Pembrolizumab 22 months Subcutaneous
nodules
None Skin granuloma (skin) None Not
recovered/
not
resolved
No SD
33 (male) IV (M1b) None LGX818/MEK162
(logic-2 study,
NCT02159066)
4 months for
cutaneous
disease, and
21 months for
pulmonary
disease
Subcutaneous
nodules
Bilateral lung
lesions
Noncaseating
granuloma (lower left
lung)
Erythema nodosum
(skin)
Systemic and
topical
corticosteroids
Remission No PR
57 (male) IIIB None Ipilimumab vs.
nivolumab (BMS
238 study,
NCT02060188)
3 months Erythematous
papules in old
scars
Mediastinal and
hilar
lymphadenopathy
Skin granuloma (skin) Topical
corticosteroids
Remission No SD
65 (male) IV None Pembrolizumab and
epacadostat/
placebo (keynote-
252 study,
NCT02752074)
1 month Subcutaneous
nodules
Mediastinal and
hilar
lymphadenopathy
Noncaseating
granuloma
(mediastinal lymph
nodes)
Skin granuloma (skin)
Systemic and
topical
corticosteroids
Remission No PD and
death
59 (male) IIB None None – None Mediastinal and
hilar
lymphadenopathy
Lipogranulomatosis
(axillary lymph nodes)
None Not
recovered/
not
resolved
– SD
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
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depth 1.1 mm, no ulceration), with satellite metastases
without metastatic nodes. He had two local recurrences
in 2013 and 2014, both followed by resection. In 2015, he
underwent a new surgery owing to a third local recur-
rence, and afterward, he was included in an adjuvant trial
of nivolumab versus ipilimumab (NCT02060188). The
study drugs were well tolerated apart from the develop-
ment of an autoimmune thyroiditis requiring replace-
ment therapy. In December 2015, the patient presented
with erythematous papules in all his old scars at the left
thumb, knee, thigh, and lower leg (Fig. 2a and b). Skin
biopsy showed sarcoid-like granulomatous infiltration in
the upper dermis, a so-called scar sarcoidosis (Fig. 2b).
PET-CT scan revealed multiple enlarged mediastinal
lymph nodes with FDG-positive activity. The skin
lesions were treated successfully with topical class III
steroids (mometasone furoate). The hilar lymphadeno-
pathy regressed spontaneously after 6 months. The
melanoma is still in complete regression (08/2017), and
the patient has no flare-up of granulomatous reactions.
Discussion
Sarcoidosis is a systemic inflammatory disease of unknown
etiology characterized by the formation of noncaseating gran-
ulomas in multiple organ systems. The development of this
disorder is defined by an extended type 1 helper-like cells
(Th1) immune response, which is primarily inducted by the
presence of CD4+Th1 cells, which interact with antigen-
presenting cells and initiate the formation and maintenance of
centrally organized collections of epitheloid histiocytes and
macrophages surrounded by giant cells and lymphocytes (non-
necrotizing granulomas). Activated CD4+T-cells differ-
entiate into Th1, thus leading to IL-2 and INF-γ secretion
and secondarily tumor necrosis factor (TNF-α) production,
through the activation of antigen-presenting macrophages
[6,7]. This chronic cytokine stimulation consists of pleo-
morphic manifestations, affecting various organs, mainly the
lungs, the lymph nodes, and the skin. The clinical spectrum of
the disease often includes systemic symptoms, such as fatigue,
night sweats, and weight loss, as well as pulmonary and
extrapulmonary signs.
Fig. 1
(a) Cutaneous sarcoidosis lesions on the left elbow with erythematous papules. (b) Histopathological characteristics with HES staining. Biopsy of the
site shown in (a) showed granulomas infiltrates. (c) Computed tomography scan showing enlarged bilateral, hilar lymph nodes.
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The association between sarcoidosis and malignant disease
has been discussed controversially in the literature [8,9].
Hematologic malignancies and solid tumors, including
melanoma, have been associated with sarcoidosis and
vice versa; previous data seem to describe a possibility of an
increased incidence of malignancies in patients with sarcoi-
dosis, although an etiological correlation is not known [10].
Sarcoidosis may present before, during, or after the diagnosis
of cancer. Moreover, therapy of the malignancy can either
induce or flare a sarcoidosis.
Most of the reported cases of SLRs in patients with
melanoma have been associated with immunotherapy
(Table 2). Although immune checkpoint inhibitors tar-
geting CTLA-4 and PD-1 or its ligand (PD-L1) are able to
provide durable responses and significant survival benefit
in advanced melanoma [27–29], many patients will often
develop manifestations of autoimmunity (irAEs) [3,4] such
as colitis and pneumonitis [30]. It has been previously
shown that the CTLA-4 blockade results in an increase in
Th17 CD4+ cells in peripheral blood, thus leading to an
extended production of proinflammatory molecules, such
as IL-6 and TNF-α [18]. IL-2 secretion by activated T
cells is besides assumed to be involved in the pathogen-
esis of sarcoidosis [31]. Recently, it was shown that PD-1
pathway is upregulated in sarcoidosis [32]. Even though
sarcoidal PD-1+CD4+T cells display reduced prolifera-
tion rate, their proliferation capacity can recover after
treatment with anti-PD-1, suggesting a potential benefit
and a dual role of PD-1 blockade in sarcoidosis, similar to
TNF-α blockers [32].
On the contrary, BRAF and MEK inhibitors have been
reported to induce a variety of dermatological toxic effects,
including granulomatous eruptions, panniculitis, and erythema
nodosum-like lesions [11,12,15,33,34]. Although the devel-
opment of SLRs seems to be a paradoxical adverse event of
the BRAF/MEK inhibitors, recent data confirm their immu-
nomodulatory effect on the tumor microenvironment. The
inhibition of the MAPK pathway has been associated with
increased CD8+T-cell infiltration and PD-L1 expression
[35]. The pathogenesis of the SLRs could be moreover
explained by the increased levels of TNF-α and IFN-γ,
which can induce the granuloma formation [12].
Fig. 2
(a, b) Multiple, erythematous papules in old scars of the left thumb and lower leg (scar-sarcoidosis). (c) Histopathological features: granulomatous
infiltration in the upper dermis.
Table 2 Case reports of sarcoid-like granulomatous reactions in
selected studies induced by immunotherapy and targeted therapy
in patients with melanoma
References Melanoma treatment
Adam et al. [11] Vemurafenib
Lheure et al. [12] Vemurafenib
Park et al. [13] Vemurafenib and dabrafenib
Green et al. [14] Dabrafenib and trametinib
Moessner et al. [15] Vemurafenib and dabrafenib, and trametinib
Seve et al. [9] Ipilimumab
Eckert et al. [16] Ipilimumab
Tissot et al. [17] Ipilimumab
Vogel et al. [18] Ipilimumab
Berthod et al. [19] Ipilimumab
Reule and North [20] Ipilimumab
Wilgenhof et al. [21] Ipilimumab
Murphy et al. [22] Ipilimumab
Andersen et al. [23] Ipilimumab
Danlos et al. [24] Nivolumab
Koelzer et al. [25] Ipilimumab and nivolumab
Reuss et al. [26] Ipilimumab and nivolumab
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In most of the cases, the SLR presented mostly a benign,
uncomplicated disease. The cutaneous sarcoidal mani-
festations can be treated with potent topical steroids, as
in the majority of our cases, thereby preventing an
immune therapy discontinuation [13]. Spontaneous
resolution of the skin lesions has also been reported.
However, patients with severe systemic involvement
may require corticosteroids or other immunosuppressants
for symptomatic relief, although these agents might have
a negative effect on the efficacy of the melanoma
treatment.
Conclusion
Our observations indicate that SLRs can appear both
under kinase and immune checkpoint inhibitors, sug-
gesting an immune response against melanoma as one
possible causative event in granuloma formation.
Awareness of sarcoidal reactions and their radiologic
features can avoid misdiagnosis of disease progression
and unnecessary treatment changes, thus suggesting the
elimination of metastatic disease and the complete eva-
luation of the symptoms as crucial.
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